Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02745730
Other study ID # REF-ICE-2421
Secondary ID
Status Completed
Phase N/A
First received April 4, 2016
Last updated November 18, 2016
Start date March 2016
Est. completion date October 2016

Study information

Verified date November 2016
Source Unilever R&D
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Resting state functional magnetic resonance imaging (rsfMRl) of the brain is used to measure pleasantness after consumption of four different milkshakes with added sugars or sweeteners.


Description:

The central role of the brain in regulating food intake and steering feeding behaviour is increasingly recognized. It is currently well accepted that the brain is the target organ to measure the effects of pleasantness and energy homeostasis in order to change feeding behaviour to reduce the rising prevalence of obesity. The effects of food on the brain are multiple and complex. In addition to primary aspects of food such as taste, texture, looks and smell, secondary aspects such as energy regulation are as much important in the entire "eating experience". Resting state functional connectivity in the brain can be assessed by the analysis of low-frequency fluctuations present in the blood-oxygenation-level-dependent (BOLD) signal in functional magnetic resonance imaging (fMRI). Investigators will use resting state functional magnetic resonance imaging (rsfMRl) to detect changes in connectivity in the default mode and salience network after consumption of four different milkshakes with added sugars or sweeteners.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2016
Est. primary completion date June 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria:

- Signed informed consent

- Age between 18 and 25 years

- BMI between 20 and 23 kg/m2

- Weight above 70 kg

- Length between 170 and 190 centimetres

Exclusion Criteria:

- Diabetes or history of other disturbances of glucose metabolism (eg impaired glucose tolerance, hypoglycaemia).

- Any genetic or psychiatric disease (e.g. fragile X syndrome, major depression) affecting brain

- Any know food allergy or intolerance

- Any significant chronic disease

- Renal or hepatic disease

- Recent weight changes or attempts to lose weight (> 3 kg weight gain or loss, within the last 3 months)

- Smoking (current or last 6 months)

- Alcohol consumption of more than 21 units per week or use of recreational drugs at present or in the last year

- Recent blood donation (within the last 2 months)

- Recent participation in other biomedical research projects (within the last 3 months), participation in 3 or more biomedical research projects in one year

- Contra-indication to MRI scanning:

- Claustrophobia

- Pacemakers and defibrillators

- Nerve stimulators

- Intracranial clips

- intraorbital or intraocular metallic fragments

- Cochlear implants

- Ferromagnetic implants

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
Glucose

Fructose

Sucralose

Allulose


Locations

Country Name City State
Netherlands Leids Universitair Medisch Centrum Leiden Zuid-Holland

Sponsors (2)

Lead Sponsor Collaborator
Unilever R&D Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other 4. Change from baseline in the connectivity in the default mode and salience network: glucose vs allulose; glucose vs sucralose; fructose vs sucralose and fructose vs allulose. Six minutes before (baseline) and 12 minutes after (response) test product intake No
Other Changes from baseline in the BOLD signal Using whole brain approach as well as seed based (hypothalamus, prefrontal cortex, nucleus accumbens, Ventral Tegmental Area, Amygdala). Six minutes before (baseline) and 12 minutes after (response) test product intake No
Primary Change from baseline in the connectivity in the default mode and salience network: glucose and fructose vs. sucralose and allulose. Six minutes before (baseline) and 12 minutes after (response) test product intake No
Secondary 2. Change from baseline in the connectivity in the default mode and salience network: glucose vs. fructose. Six minutes before (baseline) and 12 minutes after (response) test product intake No
Secondary 3. Change from baseline in the connectivity in the default mode and salience network: allulose vs. sucralose. Six minutes before (baseline) and 12 minutes after (response) test product intake No
See also
  Status Clinical Trial Phase
Completed NCT05352503 - The Effects of Making Pregnant Women With Preterm Birth Threat Watch Nature Images With Virtual Reality Goggles on the Levels of Stress, Anxiety, Attachment, and Care Satisfaction N/A